Last reviewed · How we verify
NCT05304949
Regulatory PMS Study for Lucentis® in Patients With Retinopathy of Prematurity
trial testing Lucentis in Retinopathy of Prematurity in 69 participants. Completed in 11 January 2025.
11 January 2025
Quick facts
| Lead sponsor | Novartis Pharmaceuticals |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 69 |
| Start date | 22 June 2022 |
| Primary completion | 11 January 2025 |
| Estimated completion | 11 January 2025 |
| Sites | 6 locations across South Korea |
Drugs / interventions tested
- Lucentis — full drug profile →
Conditions studied
- Retinopathy of Prematurity — all drugs for Retinopathy of Prematurity →
Sponsor
Novartis Pharmaceuticals — full company profile →
Who can join
Adults 0 to 10, any sex, with Retinopathy of Prematurity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study was an open-labeled, multicenter, single arm, observational post-marketing surveillance study under routine clinical practice with no mandated treatments, visits or assessments.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05304949
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Lucentis
Trials testing the same drug.
- NCT07515079 — Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Diabetic Macular Edema · Phase 3 · recruiting
- NCT05439629 — Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration · Phase 3 · completed
- NCT05003245 — Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD · Phase 3 · completed
- NCT05297292 — A Study to Evaluate the Efficacy and Safety of MW02 in the Treatment of nAMD · Phase 2, PHASE3 · unknown
- NCT04063358 — Anti-VEGF Intravitreous Injections for Diabetic Macular Edema in Patients Undergoing Cataract Surgery · Phase 3 · unknown
Other recruiting trials for Retinopathy of Prematurity
Currently open trials in the same condition.
- NCT05558059 — Imaging Retinal Vasculature in Infant Eyes · recruiting
- NCT06672913 — Impact of Standardized Skin-to-Skin Care on Clinical Outcomes in Infants Born ≤ 32 Weeks: A Multicenter Study · NA · recruiting
- NCT06109285 — Validation of i-ROP DL to Detect More Than Mild ROP · NA · active not recruiting
- NCT06315556 — An Observational Study to Collect Data on How Aflibercept (Eylea) Given Using a Paediatric Dosing Device is Used in Pret · recruiting
- NCT06265363 — Evaluation of the Frequency, Risk Factors, and Outcomes of ROP in Infants With a BW >1500 Grs or GA ≥33 Wks in Turkey. · recruiting
Other Novartis Pharmaceuticals trials
Trials by the same sponsor.
- NCT07498335 — Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary · Phase 3 · not yet recruiting
- NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 4 · not yet recruiting
- NCT07484269 — PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan · not yet recruiting
- NCT07416162 — A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy · not yet recruiting
- NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05304949 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Novartis Pharmaceuticals
- Last refreshed: 4 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05304949.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing